Archives

Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026

B 38% response rate and 85% disease control rate at recommended dose in advanced/metastatic NRAS and BRAF Class II/III melanoma following failure of standard therapy Responses observed across multiple RAS/MAPK-driven…

Read MoreNested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026

Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting

B IMT-009 was generally well tolerated as monotherapy and in combination with fruquintinib, demonstrating early signs of anti-tumor activity in heavily pretreated patients Translational findings suggest biomarkers associated with tertiary…

Read MoreImmunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting

Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting

B Data demonstrate robust and durable anti-cancer activity of ATX-295, a potentially best-in-class KIF18A inhibitor, in multiple preclinical chromosomally instable cancer models LEXINGTON, Mass., April 17, 2026 /PRNewswire/ — Accent Therapeutics,…

Read MoreAccent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting